A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 — ILLUMINATE-A

Primary Hyperoxaluria Type 1 (PH1) Clinical Trial

Official title:
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hyperoxaluria, Primary
Primary Hyperoxaluria Type 1 (PH1)

Clinical Trial Details

NCT number	NCT03681184
Study type	Interventional
Source	Alnylam Pharmaceuticals
Contact
Status	Completed
Phase	Phase 3
Start date	November 27, 2018
Completion date	January 12, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03847909` - A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2	Phase 2
Completed	`NCT02706886` - Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1	Phase 1/Phase 2
Enrolling by invitation	`NCT04042402` - Long Term Extension Study in Patients With Primary Hyperoxaluria	Phase 3
Active, not recruiting	`NCT03905694` - A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1	Phase 3
Available	`NCT05993416` - Treatment of Primary Hyperoxaluria Type 1 With Nedosiran